“Boule du biceps” in dysferlinopathy
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Eymard et al.1 first described “boule du biceps” (bulging of biceps), a ball-like appearance caused by the selective atrophy of the distal half of the biceps brachii (BB) muscle, in patients with dysferliniopathy. This sign is also known as biceps lump. In our cohort of 24 patients with dysferlinopathy (22 symptomatic and 2 asymptomatic hyperCKemia), all confirmed both by the absence of dysferlin on muscle biopsy and by the presence of DYSF mutation on genetic analysis, except for 4 patients who were diagnosed only at the protein level. Among the 20 patients who were genetically confirmed, 18 were homozygotes for 3 different recurrent (c.342+1G>A, c.755C>T, and c.4431G>T) and 3 different nonrecurrent (c.1958delG, c.3944_3948delinsG, and c.5983_5984del) mutations, and 2 were compound heterozygotes of mutations different from those in other patients (c.2190dupA/c.3597G>A and c.4101G>A/c.6124C>T, respectively). Of note, we did not try to subclassify the clinical phenotype into Miyoshi myopathy and LGMD2B/LGMD-R2 dysferlin related as recent articles suggest that there is no essential difference in the pattern of muscle involvement, and thus, they are the same disease.2–5 The BB was carefully observed during contraction and relaxation to check for the sign. The function of the upper limb (UL) was assessed using the Medical Research Council (MRC) scale. Furthermore, the BB was observed in patients with other muscular dystrophy in our cohort (DMD/BMD 118 cases, sarcoglycanopathy 12 cases, FSHD 5 cases, LGMD2A 18 cases, and other LGMDs 5 cases). Boule du biceps was observed in 71% (17/24) of our patients with dysferlinopathy, including the 2 asymptomatic ones. The UL MRC score was 4 or higher in the 17 patients who showed boule du biceps, but was 3+ or lower in the 7 patients who lacked the sign. None of the controls showed boule du biceps. MRI of the BB of the asymptomatic patient during arm flexion showed that the distal part of the short head was partially infiltrated by fat, whereas the long head and the proximal part of the short head were spared. MRI of the symptomatic patient showed moderate fat infiltration in the long head and in the distal part of the short head, whereas the proximal part of the short head was spared (figure). The sign was absent in patients with more marked muscle weakness, suggesting that even the proximal portion of the BB may be affected in the advanced stages and thus can no longer show contraction. Five of 7 patients who did not show boule du biceps were nonambulant, indicating that this sign disappears in advanced stage of the disease. Our findings suggest that the distal portion of the short head of the BB is affected even in early stages, whereas the proximal part is spared, which gives rise to boule du biceps. This can be a valuable diagnostic clinical feature for dysferlinopathy from early stages of the disease.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- Received July 12, 2019.
- Accepted in final form October 2, 2019.
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Emily Gilmore and Dr. Rachel Beekman
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studiesC. Paradas, J. Llauger, J. Diaz-Manera et al.Neurology, June 23, 2010 -
Articles
Symptomatic dysferlin gene mutation carriers: Characterization of two casesI. Illa, N. De Luna, R. Domínguez-Perles et al.Neurology, February 07, 2007 -
Resident and Fellow Section
Clinical Reasoning: A 30-year-old man with progressive weakness and atrophyColin Quinn, Steven A. Moore, Tanya M. Bardakjian et al.Neurology, November 07, 2016 -
Article
The Clinical Outcome Study for dysferlinopathyAn international multicenter studyElizabeth Harris, Catherine L. Bladen, Anna Mayhew et al.Neurology: Genetics, August 04, 2016